-
3
-
-
33645816753
-
-
Wu G., Barth R.F., Yang W., Lee R.J., Tjarks W., Backer M.V., and Backer Joseph M. Anticancer Agents Med. Chem. 6 (2006) 167
-
(2006)
Anticancer Agents Med. Chem.
, vol.6
, pp. 167
-
-
Wu, G.1
Barth, R.F.2
Yang, W.3
Lee, R.J.4
Tjarks, W.5
Backer, M.V.6
Backer Joseph, M.7
-
4
-
-
20344394447
-
-
Barth R.F., Coderre J.A., Vicente M., Graca H., and Blue T.E. Clin. Cancer Res. 11 (2005) 3987
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 3987
-
-
Barth, R.F.1
Coderre, J.A.2
Vicente, M.3
Graca, H.4
Blue, T.E.5
-
5
-
-
0000323139
-
-
Soloway A.H., Tjarks W., Barnum B.A., Rong F.G., Barth R.F., Codogni I.M., and Wilson J.G. Chem. Rev. 98 (1998) 1515
-
(1998)
Chem. Rev.
, vol.98
, pp. 1515
-
-
Soloway, A.H.1
Tjarks, W.2
Barnum, B.A.3
Rong, F.G.4
Barth, R.F.5
Codogni, I.M.6
Wilson, J.G.7
-
6
-
-
26844537872
-
-
and references cited therein
-
Banfi L., and Riva R. Org. React. (2005) 65 and references cited therein
-
(2005)
Org. React.
, pp. 65
-
-
Banfi, L.1
Riva, R.2
-
7
-
-
0346494442
-
-
Peacock G., Sidwell R., Pan G., Oie S., and Lu D.R. J. Pharm. Sci. 93 (2004) 13
-
(2004)
J. Pharm. Sci.
, vol.93
, pp. 13
-
-
Peacock, G.1
Sidwell, R.2
Pan, G.3
Oie, S.4
Lu, D.R.5
-
8
-
-
0037436927
-
-
Alanazi F., Li H., Halpern D.S., Oie S., and Lu D.R. Int. J. Pharm. 255 (2003) 189
-
(2003)
Int. J. Pharm.
, vol.255
, pp. 189
-
-
Alanazi, F.1
Li, H.2
Halpern, D.S.3
Oie, S.4
Lu, D.R.5
-
10
-
-
0342368730
-
-
Maletínska L., Blakely E.A., Bjornstad K.A., Deen D.F., Knoff L.J., and Forte T.M. Cancer Res. 60 (2000) 2300
-
(2000)
Cancer Res.
, vol.60
, pp. 2300
-
-
Maletínska, L.1
Blakely, E.A.2
Bjornstad, K.A.3
Deen, D.F.4
Knoff, L.J.5
Forte, T.M.6
-
17
-
-
61849099300
-
-
Zhu Y., Nong L.C., Zhao L.C., Widjaja E., Hwei C.Si., Wang C., Tan J., Van Meurs M., Hosmane N.S., and Maguire J.A. Organometallics 28 (2009) 60
-
(2009)
Organometallics
, vol.28
, pp. 60
-
-
Zhu, Y.1
Nong, L.C.2
Zhao, L.C.3
Widjaja, E.4
Hwei, C.Si.5
Wang, C.6
Tan, J.7
Van Meurs, M.8
Hosmane, N.S.9
Maguire, J.A.10
-
18
-
-
54249089741
-
-
Meshcheryakov V.I., Zheng C., Kudinov A.R., Maguire J.A., and Hosmane N.S. Organometallics 27 (2008) 5033
-
(2008)
Organometallics
, vol.27
, pp. 5033
-
-
Meshcheryakov, V.I.1
Zheng, C.2
Kudinov, A.R.3
Maguire, J.A.4
Hosmane, N.S.5
-
19
-
-
47949106498
-
-
Zhu Y., Koh C., Peng A.T., Emi A., Monalisa W., Loo K.-J.L., Hosmane Narayan S., and Maguire J.A. Inorg. Chem. 47 (2008) 5756
-
(2008)
Inorg. Chem.
, vol.47
, pp. 5756
-
-
Zhu, Y.1
Koh, C.2
Peng, A.T.3
Emi, A.4
Monalisa, W.5
Loo, K.-J.L.6
Hosmane Narayan, S.7
Maguire, J.A.8
-
21
-
-
0036783897
-
-
Valliant J.F., Guenther K.J., King A.S., Morel P., Schaffer P., Sogbein O.O., and Stephenson K.A. Coord. Chem. Rev. 232 (2002) 173
-
(2002)
Coord. Chem. Rev.
, vol.232
, pp. 173
-
-
Valliant, J.F.1
Guenther, K.J.2
King, A.S.3
Morel, P.4
Schaffer, P.5
Sogbein, O.O.6
Stephenson, K.A.7
-
24
-
-
66449091059
-
-
note
-
+, 100%].
-
-
-
-
25
-
-
66449136128
-
-
note
-
+, 100%].
-
-
-
-
26
-
-
66449107310
-
-
note
-
+, 100%].
-
-
-
-
27
-
-
66449127239
-
-
note
-
oC in DMEM containing 10% fetal bovine serum and 1% primocin. Cells were plated in 96-well plates at 2000 cells per well and were allowed to adhere for 18 h. Cells were then treated with each compound (50 μM) or with 0.3% DMSO alone for 18 h. The MTS tetrazolium salt assay was used for determining the number of remaining viable cells after exposure to compounds. Twenty microliters of MTS were added to 100-μl culture medium in each well. After incubation at 37 °C for three hours, absorbance at 490 nm was measured using an ELISA plate reader. MTS is converted to a formazan dye by the enzyme dehydrogenase found in the active cells. The quantity of formazan product measured by absorbance at 490 nm is directly proportional to the number of living cells in culture. Percent survival represents the ratio of viable cells remaining in compound-treated cells to viable cells remaining in DMSO-treated cells. As mentioned earlier, all the compounds that were tested under these conditions proved to be non-toxic at 50 μM.
-
-
-
|